Read this article in 中文 Français Deutsch Italiano Português Español
Drug firm Eli Lilly to build $6bn Alabama manufacturing plant
10 December 2025
Drug firm Eli Lilly has announced plans to invest $6 billion in a new manufacturing plant in Huntsville, Alabama, USA.
A digital render of the Eli Lilly plant planned for construction in Huntsville, Alabama, USA (Image: Eli Lilly)
The next-generation synthetic medicine active pharmaceutical ingredient (API) facility is the third of four new sites the company plans to announce.
It will produce small-molecule synthetic and peptide medicines.
Construction is set to start in 2026 and will generate around 3,000 jobs, ahead of expected completion in 2032.
Eli Lilly selected the Greenbrier South, Huntsville, Alabama site from more than 300 applications.
The company said the decision was based on its proximity to the HudsonAlpha Institute for Biotechnology, as well as workforce potential, access to utilities, transportation and favourable zoning and incentives.
Earlier this year, the company announced plans to boost its domestic production of medicines, revealing planned construction od sites in Texas (pictured) and Virginia, as well as expanding an existing site in Puerto Rico.
Another US location is set to be announced in the coming weeks.
STAY CONNECTED
Receive the information you need when you need it through our world-leading magazines, newsletters and daily briefings.
CONNECT WITH THE TEAM
